Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott announced “exciting” collaboration with GSK

Abbott announced “exciting” collaboration with GSK

14th July 2009

Abbott has announced a collaborative project with GlaxoSmithKline (GSK), which will see the two companies work together to develop a molecular diagnostic test aimed at screening for non-small cell lung cancer tumours for the expression of the MAGE-A3 antigen.

Under the terms of the deal, the two firms will develop and commercialise a polymerase chain reaction (PCR) test that is designed to detect MAGE-A3 – a tumour-specific antigen not expressed in normal cells.

The test will be used on Abbott’s m2000 automated instrument system.

Commenting on the move, Stafford O’Kelly, head of the molecular diagnostics business at Abbott, said: “This is an exciting collaboration with a leading company in cancer immunotherapy research.”

The agreement is indicative of the firm’s focus on medicine that is personalised, as well as its commitment to developing analytical molecular devices to identify individuals that are most likely to benefit from key pharmacogenomic therapies, he added.

Abbott is set to announce its earnings for the second quarter of 2009 in July 15th.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.